Presley said Gentherm has been working to develop commercial vehicle and heavy-duty equipment channels organically, and that the transaction provides established commercial channels that could accelerate cross-selling of Gentherm’s existing products into a broader customer base. He also pointed to power generation as a key growth market, citing demand for reliable energy for mission-critical operations such as data centers and increased need for backup power amid aging and unstable grid infrastructure.Chief ...

Creating a Premier Global Climate Solutions Company January 29, 2026 Forward-Looking Statements and RMT Disclaimer No Offer or Solicitation This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registratio ...

Core Thesis - Amentum Holdings, Inc. is positioned as a leading government technology contractor following its merger with Jacobs Solutions, creating a scaled entity with significant revenue and backlog [2][3] Company Overview - Amentum provides engineering and technology solutions to U.S. and allied government agencies, with a pro forma revenue near $14 billion and a backlog exceeding $44.6 billion [2][3] - The company has over 53,000 employees across 80 countries, enhancing its competitive positioning against Tier 1 incumbents like Leidos and Booz Allen Hamilton [3] Financial Metrics - As of November 28th, Amentum's share price was $28.63, with trailing and forward P/E ratios of 106.04 and 12.03 respectively [1] - The market currently undervalues Amentum, pricing it at a forward P/E of 10.4x, reflecting a typical "conglomerate discount" [5] - The company has an Owner Earnings yield of 10.8%, indicating strong free cash flow generation and deleveraging potential [6] Strategic Initiatives - Key value drivers include anticipated cost synergies of $50–70 million, aggressive debt paydown, and expansion of the Digital Solutions segment, which has shown 8% EBITDA margins [5] - Recent contract wins, including a $946 million U.S. Army contract and $350 million in digital task orders, validate the strategic rationale behind the merger [6] Growth Potential - With net leverage improving to 3.5x and a strong pipeline, Amentum presents a compelling risk/reward profile, with potential stock valuation reaching mid-$30s or even $42 with successful growth [7] - The combination of stable revenue, high free cash flow, and operational scale makes Amentum an attractive investment opportunity in the government technology sector [7] Historical Performance - Amentum's stock price has appreciated approximately 53.34% since March 2025, reflecting the successful execution of the bullish thesis on the company [8]

Core Insights - Becton, Dickinson and Company (BDX) and Waters Corporation (WAT) have announced a strategic collaboration to merge BD's Biosciences Diagnostic Solutions business with Waters' analytical technologies expertise, creating a new entity focused on high-throughput testing in life sciences and diagnostics [1][9] Transaction Details - The merger has been unanimously approved by both companies' boards and is expected to close by the end of Q1 2026, pending regulatory and shareholder approvals [2] - BD will receive $4 billion in cash and hold a 39.2% stake in the new entity through a Reverse Morris Trust structure [8][12] Financial Projections - The combined company aims for $6.5 billion in revenues by 2025, with projections of reaching $9 billion and $3.3 billion in EBITDA by 2030 [8][11] - The total addressable market is expected to double to approximately $40 billion, allowing access to adjacent segments [10] Synergy and Growth Potential - The merger is projected to generate approximately $200 million in cost synergies by the third year post-closing and $290 million in revenue synergies by the fifth year [13] - Annualized EBITDA gains of about $345 million are anticipated by 2030, reinforcing the long-term value creation potential of the transaction [13] Market Position and Performance - BD currently has a market capitalization of $50.76 billion and an earnings yield of 8.1%, outperforming the industry average of 5.3% [5] - BDX shares have lost 21.9% year-to-date, contrasting with a 6.1% gain in the S&P 500 during the same period [3]

Core Viewpoint - Waters Corporation and BD have announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters, creating a leading entity in life sciences and diagnostics valued at approximately $17.5 billion [1][2]. Strategic and Financial Benefits - The transaction is expected to create substantial shareholder value through a strong strategic fit, increasing Waters' total addressable market to approximately $40 billion with an annual growth rate of 5-7% [2][3]. - Pro forma expected sales for the combined company in 2025 are approximately $6.5 billion, with adjusted EBITDA around $2.0 billion [2][9]. - The combined entity anticipates over 70% of its revenue to be recurring, with significant contributions from market-leading brands [2][3]. - Expected annualized EBITDA synergies of approximately $345 million by 2030, including $200 million in cost synergies by year three and $290 million in revenue synergies by year five [2][4]. - The transaction is projected to be accretive to adjusted EPS in the first year, with mid-to-high single-digit revenue growth and mid-teens annualized adjusted EPS growth expected over five years [2][9]. Technological and Market Expansion - The merger will bring together complementary technologies, enhancing capabilities in high-volume testing across regulated markets, including liquid chromatography and mass spectrometry [3][4]. - The combined company aims to accelerate expansion into high-growth adjacent markets, leveraging Waters' chemistry expertise and BD's biologics knowledge [3][4]. - BD's regulatory expertise is expected to enhance market access and service support, particularly in multiplex diagnostics using Waters' technologies [3][4]. Management and Governance - Udit Batra, Ph.D., will lead the new entity, with key leadership roles filled by executives from both companies [11][12]. - The combined company will operate under the Waters name and maintain its listing on the New York Stock Exchange [12]. Financial Structure and Transaction Details - The transaction is structured as a Reverse Morris Trust, with BD shareholders expected to own approximately 39.2% of the combined company and Waters shareholders approximately 60.8% [10]. - BD will receive a cash distribution of approximately $4 billion prior to the completion of the combination [10]. - The transaction is expected to close around the end of the first quarter of 2026, pending regulatory approvals and other customary conditions [10].